Stockscreener 앱 받기
2.9517
7.18%
-0.2283
시간 외 거래:
2.83
-0.1217
-4.12%
전일 마감가:
$3.18
열려 있는:
$3.11
하루 거래량:
41,903
Relative Volume:
1.21
시가총액:
$26.34M
수익:
-
순이익/손실:
$-8.24M
주가수익비율:
-1.8921
EPS:
-1.56
순현금흐름:
$-16.44M
1주 성능:
-15.67%
1개월 성능:
-20.22%
6개월 성능:
-27.79%
1년 성능:
+13.53%
1일 변동 폭
$2.9101
$3.20
1주일 범위
$2.8205
$3.44
52주 변동 폭
$2.4377
$6.1568
마커 테라퓨틱스 Stock (MRKR) Company Profile
명칭
Marker Therapeutics Inc
전화
(713) 400-6400
주소
2450 HOLCOMBE BLVD, HOUSTON, TX
MRKR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| MRKR | 2.9517 | 26.34M | 0 | -8.24M | -16.44M | -1.56 |
| VRTX | 450.37 | 115.10B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.07B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.20B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 25.09B | 3.30B | -501.07M | 1.03B | 11.54 |
마커 테라퓨틱스 Stock (MRKR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-25 | 개시 | Piper Sandler | Overweight |
| 2021-03-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-05-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2019-05-30 | 개시 | ROTH Capital | Buy |
| 2019-03-01 | 개시 | Janney | Buy |
| 2018-12-03 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
모두보기
마커 테라퓨틱스 주식(MRKR)의 최신 뉴스
Hematopoietic Stem Cell Transplantation Market to Exhibit - openPR
Silence Therapeutics' Zerlasiran Shows 90% Reduction in Key Heart Disease Marker | SLN Stock News - StockTitan
Marker Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Precision Optics Receives Initial Production Order for Single-Use Ophthalmic Program - The Manila Times
Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire
Marker Therapeutics Secures $4M NIH Grants, Reports Promising MT-601 Trial Progress | MRKR Stock News - StockTitan
Marker Therapeutics Inc (MRKR) Quarterly 10-Q Report - Quartzy
Alterity's Advanced Brain Imaging Breakthrough Reveals New MSA Disease Progression Marker | ATHE Stock News - StockTitan
Dr Truong on the Background of the ImmunoCobiVem Trial in BRAF V600+ Melanoma - OncLive
MAGEA4 Opens the Door for Engineered Cellular Therapies in Solid Tumors - OncLive
US Penny Stocks To Consider In October 2024 - Simply Wall St
Allogeneic Hematopoietic Stem Cell Transplant Market to - GlobeNewswire
Allogeneic Hematopoietic Stem Cell Transplant Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - India Shorts
Kids Marker Market to hit USD 257.4 million by 2032, says Global Market Insights Inc. - Yahoo Finance
PLK-1 Inhibitors Market to Register Immense Growth by 2034 | DelveInsight - PR Newswire UK
Omega Therapeutics stock hits 52-week low at $1.2 - Investing.com
AML cell therapy trials to watch in 2024 targeting GvHD - Yahoo Finance
Markforged (NYSE:MKFG) Sees Unusually-High Trading Volume - Defense World
Top 3 Health Care Stocks That May Explode This Month - EMEA Tribune, Breaking News, World News, Latest News, Top Headlines
On Tuesday’s show: Medical 'Blind Spots' - WJCT NEWS
ProShare Advisors LLC Has $47.68 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - Defense World
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna - PR Newswire
ProShare Advisors LLC Sells 43,073 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
AI Is Poised to Influence Several Areas of Cancer Care With Some Fine-Tuning - OncLive
Meiji Yasuda Asset Management Co Ltd. Has $580,000 Position in Moderna, Inc. (NASDAQ:MRNA) - Defense World
Washington Journal: Dr. Marty Makary Discusses His Book "Blind Spots" & Health Care in the U.S. - C-SPAN
Moderna Inc. stock underperforms Friday when compared to competitors - MarketWatch
Hematopoietic Stem Cell Transplantation Global Market Report 2024 Size and Forecast - WhaTech
Edgestream Partners L.P. Invests $1.67 Million in Moderna, Inc. (NASDAQ:MRNA) - Defense World
Moderna Inc [NASDAQ: MRNA] Sees Decrease in Stock Value - Knox Daily
Hematopoietic stem cell transplantation (HSCT) Market to See - openPR
Down 13% in 1 Day, Is Moderna Stock in Trouble? - The Motley Fool
Quest Partners LLC Trims Stock Position in Marsh & McLennan Companies, Inc. (NYSE:MMC) - MarketBeat
Moderna Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Parallel Advisors LLC Reduces Position in Moderna, Inc. (NASDAQ:MRNA) - Defense World
Pfizer Inc (PFE-N) QuotePress Release - The Globe and Mail
Dr. Marty Makary Talks "Blind Spots: When Medicine Gets It Wrong, and What It Means for Our Health" - The Clay Travis & Buck Sexton Show
Acadian Asset Management LLC Purchases New Position in Moderna, Inc. (NASDAQ:MRNA) - Defense World
Dai ichi Life Insurance Company Ltd Boosts Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - Defense World
AMG 193 Shows Preliminary Clinical Activity in MTAP-Deleted Solid Tumors - OncLive
Wedbush Securities Inc. Invests $393,000 in First Trust NASDAQ BuyWrite Income ETF (NASDAQ:FTQI) - Defense World
Biodesix, Inc. (NASDAQ:BDSX) Receives Average Recommendation of “Buy” from Analysts - Defense World
United Parks & Resorts Inc. (NYSE:PRKS) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor - StockTitan
Palisade Bio Reports Data Demonstrating PDE4B Expression in - GlobeNewswire
Short Interest in Solventum Co. (NYSE:SOLV) Drops By 17.8% - Defense World
VanEck Pharmaceutical ETF (NASDAQ:PPH) Short Interest Down 17.3% in August - Defense World
MYR Group Inc. (NASDAQ:MYRG) Short Interest Update - Defense World
Phillips 66 (NYSE:PSX) Shares Sold by Allspring Global Investments Holdings LLC - Defense World
Bank of New York Mellon Corp Acquires 36,810 Shares of SEI Investments (NASDAQ:SEIC) - Defense World
Anthem Blue Cross and Blue Shield unveils a new historic marker in Columbus - Yahoo Finance
마커 테라퓨틱스 (MRKR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
3.55%
자본화:
|
볼륨(24시간):